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Venomous animals have a long history as a source of 
medical treatments (1). Snake venom, for example, has 
been used in Ayurvedic medicine since the 7th century 
BCE to prolong life and treat arthritis and gastrointestinal 
ailments. Tarantulas are used by indigenous populations of 
Central and South America to treat ailments ranging from 
asthma to cancer, while cobra venom has been used since 
the 1930s to treat conditions as diverse as asthma, polio, 
multiple sclerosis, rheumatism and pain (2). However, the 
modern era of venoms-based drug discovery did not begin 
until the 1970s with the development of the blockbuster 
antihypertensive drug captopril, based on a peptide from 
the venom of the Brazilian viper Bothrops jaracaca (3). 
Today, many of the major pharmaceutical companies (and 
most major agrochemical companies) have venom-based 
drug discovery programs or use venom-derived molecules 
for target validation (e.g., AstraZeneca, Eli Lilly, Johnson 
& Johnson and Merck). Moreover, there are now several 
companies with a focus on venom-derived therapeutics, 
including Airmid, ReceptoPharm (a subsidiary of 
Nutra Pharma), Theralpha, VenomeTech, Venomics (a 
subsidiary of QRxPharma) and Xenome. In this article, I 
outline recent developments in the venoms-based drug 
discovery field that might lead to new venom-derived 
peptide therapeutics.
I n t roduc t i on 
An extraordinarily diverse range of animals, including 
arachnids, centipedes, cone snails, reptiles, squid, and 
wasps, have evolved venoms for the purpose of predation 
(4). Since the prey–predator relationship applies a constant 
selection pressure on toxin efficacy, venom toxins typically 
have extremely high specificity and potency for their 
molecular target, owing to long periods of evolutionary 
fine tuning (>400 million years in the case of scorpions 
and centipedes). These features, which are often not found 
in natural or synthetic small molecules, have made animal 
toxins extremely valuable as pharmacological tools. For 
example, a-conotoxin peptides from marine cone snails 
are invaluable tools for discriminating between closely 
related subtypes of nicotinic acetylcholine receptors (5), 
while five of the seven pharmacological sites on vertebrate 
voltage-gated sodium (NaV) channels are defined by 
animal toxins (6).
The venoms of cone snails, sea anemones and arthropod 
predators such as centipedes, scorpions and spiders 
are dominated by disulfide-rich peptides that evolved 
via explosive duplication and diversification of a small 
number of ancestral toxin genes in order to produce what 
is essentially a combinatorial library of small, bioactive 
peptides (7-9). This genetic strategy led to the evolution 
of highly complex invertebrate venoms that can contain 
more than a thousand unique peptides (10,11). In contrast 
to invertebrate venoms, most snake venoms (with elapids 
being a notable exception) are less complex and contain a 
higher proportion of larger proteins and enzymes (12,13). 
Nevertheless, regardless of source species, venom proteins 
and peptides are usually endowed with a disulfide-rich 
architecture that provides them with a high degree of 
chemical and thermal stability as well as resistance to 
proteases. It is this feature, along with their selectivity and 
potency, that has made venoms a valuable source of lead 
molecules for the development of novel therapeutics. 
The Cur rent Landscape of  Venom-derived Drugs
There are currently six FDA-approved drugs derived 
from venom peptides or proteins, with a further ten in 
clinical trials and many more in various stages of preclinical 
development (1). The majority of approved venom-
derived drugs are derived from snakes or lizards and they 
mostly target the cardiovascular system. This implies that 
optimal success in venoms-based drug discovery might 
be achieved by narrowly focusing on cardiovascular 
modulators from reptiles. However, this scenario is the 
result of two historical factors that are no longer relevant.
First, most early toxinological studies focussed on 
snakes as they typically provide much larger quantities of 
venom than other venomous animals (typically milliliters 
of venom per milking compared to less than 10 mL from 
centipedes, scorpions and spiders). The development over 
the past decade of high-throughput methods for screening 
venoms and characterising the active components (14) has 
opened up the field of venoms-based drug discovery to 
small venomous invertebrates, which constitute the vast 
majority of venomous species. Second, our understanding 
of the cardiovascular system preceded our still rudimentary 
understanding of the nervous system, which houses most 
of the molecular targets of invertebrate venoms. Exciting 
neuronal drug targets such as acid-sensing ion channels 
(ASICs), transient receptor potential (TRP) channels, 
various subtypes of voltage-gated channels, and numerous 
G protein-coupled receptors (GPCRs) had not even been 
discovered in the 1970s and 1980s. It is only now that our 
understanding of the molecular architecture of the nervous 
system has become more advanced that venom peptides 
from invertebrates are beginning to provide therapeutic 
leads for non-cardiovascular targets. A good example is 
the introduction in 2004 of Prialt®, a voltage-gated calcium 
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channel blocker used for the treatment of intractable 
chronic pain (15). Prialt®, a 25-residue peptide stabilised 
by three disulfide bridges, is identical to the native peptide 
found in the venom of a fish-hunting marine cone snail. 
Cur rent  Deve lopment s
Route of Administration of Venom-peptide Drugs
In line with an increasing industry focus on peptide 
drugs (1), the two most recently approved venom-derived 
therapeutics (Prialt® and Byetta®), as well as most venom 
molecules currently under development, are peptides 
(11–71 residues). Most are stabilised by 2–5 disulfide 
bonds (Table 1). The use of protease-resistant disulfide-
rich venom peptides that can be produced by recombinant 
methods obviates many of the historical shortcomings of 
peptide drugs, such as poor stability, low solubility and 
high cost of manufacturing. However, since it is assumed 
that most venom peptides will not be orally active, these 
drugs are generally being developed as injectable therapies. 
For life-threatening situations, perioperative use, and 
chronic conditions such as diabetes and multiple sclerosis, 
parenteral administration is unlikely to be a major limitation 
in terms of patient acceptance and market penetrance. 
However, the frequency of injection is likely to be an 
important factor, and consequently there is much interest 
in developing methods of prolonging venom-peptide half-
life in order to reduce administration frequency. There has 
been good progress in this area as evidenced by recent 
developments with exenatide, the latest venom-derived 
drug to be approved by the FDA. Exenatide is an insulin 
secretagogue (GLP-1 receptor agonist) used to treat type 
2 diabetes (16). It is a synthetic version of the 39-residue 
exendin-4 peptide isolated from the saliva of the Gila 
monster, a venomous lizard. Exenatide is a linear peptide 
with a relatively short in vivo half life and consequently the 
original formulation of this drug (Byetta®) required twice 
daily subcutaneous injections. Despite this limitation, 
Byetta® achieved worldwide sales of USD $800 million 
in fiscal 2009 (1). Eli Lilly, Amylin Pharmaceuticals and 
Alkermes subsequently developed a formulation in which 
the peptide is embedded in biodegradable polymeric 
microspheres, leading to an extended duration of exenatide 
release that enables therapeutic levels to be maintained 
with once-weekly injections (17). This new formulation 
(Bydureon®) was recently approved by the FDA and it 
has been forecast that worldwide sales will peak at USD 
$2.5 billion despite the introduction of competing incretin 
mimetics (1). This seminal work on extending the half-life 
of exenatide has provided both renewed impetus and a 
proven approach for extending the duration of action of 
other venom-peptide drugs.
The much smaller size of venom-peptides (typically <5 
kDa) compared with larger antibody-based biologics also 
opens up the possibility of using non-traditional routes 
of administration such as buccal, nasal, pulmonary and 
transdermal (18). Theralpha, for example, are currently 
testing sublingual delivery of prohanin, an 11-residue 
analgesic peptide from the venom of the King cobra, while 
buccal and intranasal delivery are being examined for 
administration of the sea anemone peptide ShK (discussed 
in more detail below) (19). What remains to be tested in any 
detail is whether the small size of venom peptides and their 
Table 1. Examples of disulfide-rich venom peptides currently in clinical or preclinical development.
The number of residues (size) and disulfide bridges (SS bonds) is indicated. Abbreviations: nAChR, nicotinic 
acetylcholine receptor; GABAB, metabotropic GABA receptor; CaV2.2, N-type voltage-gated calcium channel.
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extreme resistance to proteases might confer some level 
of oral activity. The recent demonstration (20) that oral 
activity could be conferred upon a small venom peptide by 
increasing its stability through N-to-C-terminal cyclisation 
has raised hopes that oral bioavailability might prove to be 
a general property of disulfide-rich venom peptides.
First-in-class Drugs Derived from Venoms
One of the most exciting developments in the field in recent 
years has been the emergence of new, potential first-in-class 
drugs derived from animal venoms, best exemplified by the 
development of the sea anemone venom-peptide ShK for 
treatment of multiple sclerosis (MS) and other autoimmune 
diseases. In humans, expression of the voltage-gated 
potassium channel Kv1.3 increases ~5-fold when quiescent 
effector memory T (TEM) cells terminally differentiate to 
TEM-effector cells in autoimmune diseases such as MS and 
rheumatoid arthritis (21). In contrast, Kv1.3 expression is 
virtually unchanged during activation of naïve and long-
lived central memory (TCM) T cells. Thus, selective blockade 
of Kv1.3 provides a mechanism for treating T cell-mediated 
autoimmune diseases without inducing generalised 
immunosuppression (22,23). Unfortunately, although 
many natural and synthetic compounds have been isolated 
that potently inhibit Kv1.3, most are not sufficiently 
selective to be useful therapeutics. In contrast, ShK-186, an 
ShK analogue with extremely high potency and selectivity 
for Kv1.3 (21,24), recently completed a successful Phase 
1a clinical trial for treatment of MS. Thus, ShK-186 might 
become the first-in-class Kv1.3 blocker for treatment of MS 
and other autoimmune diseases.
Another target for which venom peptides might provide 
first-in-class drugs is the voltage-gated sodium channel 
NaV1.7, a key player in the human pain signalling pathway. 
Humans with inheritable loss-of-function mutations in 
NaV1.7 are indifferent to all types of pain, with no other 
sensory impairments except anosmia (25). Thus, drugs that 
block NaV1.7 should be powerful analgesics for treating 
many chronic pain conditions. Despite intense interest within 
large pharma, development of NaV1.7-based analgesics has 
proved difficult as it is essential to avoid off-target effects 
on closely related NaV channels with critical physiological 
roles. In particular, it is essential to avoid effects on NaV1.5, 
which is responsible for the rising phase of the cardiac 
action potential, the muscle-specific NaV1.4, and NaV1.6, the 
primary NaV channel at nodes of Ranvier. Small-molecule 
NaV1.7 blockers tend to bind in the highly-conserved pore 
region of the channel, making it difficult to achieve subtype 
selectivity. In contrast, spider-venom peptides bind to the 
less well-conserved voltage sensor domains of the channel, 
providing an opportunity to obtain selective inhibition of 
NaV1.7 (6). Merck have described a number of spider-venom 
peptides that potently inhibit NaV1.7 but not with sufficient 
selectivity to be therapeutically useful (26). However, we 
recently described a centipede-venom peptide (Ssm6a) 
that not only potently inhibits human NaV1.7 but crucially 
has more than 150-fold selectivity for NaV1.7 over all other 
human NaV subtypes with the exception of NaV1.2, for 
which the selectivity is 32-fold (27). Ssm6a proved to be 
more analgesic than morphine in rodent models of pain and 
it appears to have a very high therapeutic index (27).
Future  Pro spe c t s
Key technical advances combined with a renewed 
industry-wide focus on biologics have converged to 
provide a larger-than-ever pipeline of venom-derived 
peptide therapeutics. Disulfide-rich venom peptides 
obviate some of the potential disadvantages of therapeutic 
peptides and in contrast with larger biologics, they are 
unlikely to be immunogenic. Moreover, there is growing 
appreciation that oral administration might be a viable 
option for some venom peptides (20), significantly 
enhancing the likelihood of them achieving blockbuster 
status. The fact that some venom peptides appear capable 
of breaching the blood brain barrier (28) and translocating 
across cell membranes (29) also opens up the possibility of 
exploiting targets that have not previously been accessible 
to peptide drugs.
Despite recent progress, only a tiny fraction of the 
chemical diversity encoded in animal venoms has been 
explored. Fortunately, a much wider range of animal 
venoms can now be studied in detail due to recent 
advances in analytical techniques as well as the ability 
to extract peptide sequences directly from venom-gland 
transcriptomes (14,30). These technical advances, along 
with the introduction of high-throughput screening 
platforms (14), should greatly expedite future venoms-
based drug discovery efforts and help to expand the 
growing pipeline of venom-derived drugs.
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